National Cancer Institute (U.S.)
"National Cancer Institute (U.S.)" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Component of the NATIONAL INSTITUTES OF HEALTH. Through basic and clinical biomedical research and training, it conducts and supports research with the objective of cancer prevention, early stage identification and elimination. This Institute was established in 1937.
| Descriptor ID |
D054547
|
| MeSH Number(s) |
I01.409.418.750.600.650.496.150 N03.540.052.750.150 N03.540.348.500.500.600.650.496.150
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "National Cancer Institute (U.S.)".
Below are MeSH descriptors whose meaning is more specific than "National Cancer Institute (U.S.)".
This graph shows the total number of publications written about "National Cancer Institute (U.S.)" by people in this website by year, and whether "National Cancer Institute (U.S.)" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 3 | 3 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 1 | 2 |
| 2012 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 3 | 3 |
| 2019 | 0 | 2 | 2 |
| 2020 | 0 | 2 | 2 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 4 | 4 |
| 2025 | 0 | 1 | 1 |
| 2026 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "National Cancer Institute (U.S.)" by people in Profiles.
-
Feasibility of Automated Laboratory Data Ascertainment and Transfer From Hospitals Into Medidata Rave Across Pediatric National Cancer Institute-Supported Cooperative Groups. JCO Clin Cancer Inform. 2026 Apr; 10(2):e2500359.
-
Immune Checkpoint Inhibitor-Induced Diabetes Across National Cancer Institute Trials That Included PD-1 or PD-L1 Agents. JAMA Oncol. 2026 Feb 01; 12(2):194-199.
-
Childhood cancer data initiative: expanded access to tumor molecular profiling for children, adolescents, and young adults. J Natl Cancer Inst. 2026 Feb 01; 118(2):199-204.
-
Germline Cancer Predisposition Results From the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. JCO Precis Oncol. 2025 Oct; 9:e2500742.
-
Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium. J Natl Cancer Inst. 2024 Nov 01; 116(11):1721-1729.
-
Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations. Mol Cancer Ther. 2024 Jul 02; 23(7):924-938.
-
Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. JCO Precis Oncol. 2024 Jun; 8:e2400103.
-
Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E. JCO Precis Oncol. 2024 Apr; 8:e2300454.
-
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C. J Natl Cancer Inst. 2023 11 08; 115(11):1355-1363.
-
Leveraging Clinical Trial Populations and Data from the Children's Oncology Group for Cancer Survivorship Research. Cancer Epidemiol Biomarkers Prev. 2022 09 02; 31(9):1675-1682.